A phase I, randomised, double-blind, placebo-controlled, multi-centre, ascending-dose trial to evaluate the safety, tolerability and immunogenicity of Vaccine FP-02.2 in HBeAg-negative hepatitis B patients as an add-on treatment to entecavir or tenofovir.
1st May 2016 - ongoing
Status: Active
Specialism: Liver.
Team: Dr Stephen Ryder.
People
Photo | Name | Bio |
---|---|---|
![]() |
Dr Stephen Ryder |
Publications
Title |
---|
Grants
Title | Amount |
---|